CYP21A2 gene mutationsin the women with recurrent miscarriage

Cover Page


Cite item

Full Text

Abstract

Miscarriage is one of the major problems of modern reproduction. Total frequency of micarrieges is estimated as 15–27 % of total pregnancies. Recurrent Miscarriage (RM) (three or more spontaneous abortions) is responsible for almost 20 % of total miscarrieges. The population frequency of RM fluctuates from 2 % to 5 %. One of the important causes of abortion in the first trimester are hormonal disturbances in the mother, including adrenal hyperandrogenism, which results in congenital adrenal hyperplasia (CAH). In 95 % of cases, this pathology is caused by mutations in the 21-hydroxylase gene (CYP21A2), encoding for 21-hydroxylase. A non-classical form of CAH is the leading factor in 30 % of RM in women with hyperandrogenia. The aim of this study was to investigate the role of the most common mutations in the CYP21A2 gene in women with RM for more accurate diagnosis of this pathology. The level of 17-OH-progesterone was measured in women with RM and with mutations in the gene CYP21A2. The frequency of mutations in the CYP21A2 gene in RM women was significantly higher than in the group of women who don’t have these mutations (14.4 ± 3.3 % and 2 ± 1.4 %, respectively, p <0,05 df = 1). According to the odds ratio the risk of RM in CYP21A2 mutations carriers is 8 times higher than in the women without these mutations (OR = 8.4 (1.9–37.6)). The level of 17-OH-progesterone is not associated with mutations in CYP21A2 gene in the women with RM

About the authors

Natalya Sergeevna Osinovskaya

Laboratory of prenatal diagnostics of congenial and hereditary diseases

Email: natosinovskaya@mail.ru
PhD, senior research fellow

Iskender Yuryevich Sultanov

Laboratory of prenatal diagnostics of congenial and hereditary diseases

assistant

Tatyana Eduardovna Ivaschenko

Laboratory of prenatal diagnostics of congenial and hereditary diseases

Dr. Sci, Prof., Leading Researcher

Vladislav Sergeevich Baranov

D. O. Ott Research Institute of Obstetrics and Gynecology NWB RAMS

Dr. Sci, Prof., Corresponding Member of RAMN, head of the laboratory of prenatal diagnostics of congenial and hereditary diseases

References

  1. Качалина Т. С. Гиперандрогения и невынашивание беременности // Российский вестник акушера-гинеколога. — 2004. — № 3. — С. 469–481.
  2. Кошелева Н. Г. Современная тактика лечения и профилактики невынашивания беременности с учетом этиопатогенеза // Вестник Российской ассоциации акушеров-гинекологов. — 1996. — № 3. — С. 45–51.
  3. Осиновская Н. С. Особенности проведения молекулярной диагностики при врожденной гиперплазии коры надпочечников // Молекулярно-биологические технологии в медицинской практике. — Новосибирск: Альфа-Виста, 2002. — вып. 2. — С. 111–119.
  4. Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status / Dolzan V. [et al.] // Eur. J. Endocrinol. — 1999. — Vol. 141, № 2. — P. 132–139.
  5. An unequal crossover event in RCCX modules of the human MHC resulting in the formation of a TNXB/TNXA hybrid and deletion of the CYP21A / Jaatinen T. [et al.] // Hum. Immunol. — 2002. — Vol. 63, № 8. — P. 683–689.
  6. Characterisation of CAH alleles with non-radioactive DNA single strand conformation polimorphism analysis of the CYP21 gene / Bobba A. [et al.] // J. Med. Genet. — 1997. — Vol. 34. — P. 223–228.
  7. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia / Lee H. [et al.] // J. Med. Genet. — 1996. — Vol. 33. — P. 371–375.
  8. Endocrinological and endometrial factors in recurrent miscarriage / Li T. C. [et al.] // British J. Obst. and Gynaecol. — 2000. — Vol. 107. — P. 1471–1479.
  9. Fertility in women with lateonset adrenal hyperplasia due to 21-hydroxylase deficiency / Feldman S. [et al.] // Clin. Endocrinol. Metab. — 1992. — Vol. 74. — P. 635–639.
  10. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency / Bidet M. [et al.] // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95, № 3. — P. 1182–1190.
  11. Goncalves J., Friaes A., Moura L. Congenital adrenal hyperplasia: focus on the molecular basis of 21-hydroxylase deficiency // Expert reviews in molecular medicine. — 2007. — Vol. 9, № 11. — P. 1–23.
  12. Hanukoglu I. Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis // J. Steroid Biochem. Molec. Biol. — 1992. — Vol. 43, № 8. — P. 779–804.
  13. Krone N. Genetics of congenital adrenal hyperplasia // Best Practice Res. Clin. Endocrinol. Metabolism. — 2009. — Vol. 23. — P. 181–192.
  14. Meka A., Reddy B. M. Recurrent spontaneous abortions: an overview of genetic and non-genetic backgrounds // Int. J. Hum. Genet. — 2006. — Vol. 6, № 2. — P. 109–117.
  15. New M. I. Nonclassical 21-hydroxylase deficiency // J. Clin. Endocrinol. Metabolism. — 2006. — Vol. 91, № 11. — P. 4205–4214.
  16. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia / Moran C. [et al.] // J. Clin. Endocrinol. Metabolism. — 2006. — Vol. 91, № 9. — P. 3451–3456.
  17. Sambrook J., Fritsch E. F., Maniatis T. Molecular cloning. A laboratory manual // Cold Spring Harbor Laboratory Press. — 2001. — P. 1–245.
  18. The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism Kelestimur F. [et al.] // J. Experimental clin. Endocrinol. diabetes. — 2009. — Vol. 117, № 5. — P. 205–208.
  19. White P. C., Speiser P. W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency // Endocrine reviews. — 2000. — Vol. 21, № 3. — P. 245–291.
  20. Witchel S. F., Azziz R. Nonclassic congenital adrenal hyperplasia // International journal of pediatric endocrinology. 2010. URL: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC2910408/pdf/ IJPE2010–625105.pdf. — (дата обращения 01.02.2012).

Copyright (c) 2012 Osinovskaya N.S., Sultanov I.Y., Ivaschenko T.E., Baranov V.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies